Zykadia förlänger progressionsfri överlevnad i Fas 2 studie

Novartis ALK+ metastatic NSCLC therapy Zykadia® extends progression-free survival beyond 18 months in Phase II study
Novartis meddelade idag att resultat från en Fas 2 studie visar att patienter med  (ALK+) non-small cell lung cancer (NSCLC) som tar Zykadia® (ceritinib) som första behandling fick en median progressionsfri överlevnad på 18,4 månader. Resultaten presenterades på ESMO i Köpenhamn.

These results are consistent with findings from the Phase I ASCEND-1 study, which demonstrated a median PFS of 18.4 months (95% CI: 15.2-not reached) as per BIRC assessment with a median follow-up of 11.1 months[2]. The previous analysis by BIRC in ASCEND-3 indicated that the median PFS had not been reached after a median follow-up time of 8.3 months[3].

Further, in a sub-analysis of these data, patients who entered the study with brain metastases at baseline experienced an overall response rate (ORR) of 63.3% (95% CI: 48.3-76.6) and a disease control rate (DCR) of 83.7% (95% CI: 70.3-92.7), both as measured by BIRC. These results were similar to those in patients without brain metastases, who demonstrated an ORR of 64.0% (95% CI: 52.1-74.8) and DCR of 88.0% (95% CI: 78.4-94.4), based on BIRC assessment[1].

”The unfortunate reality of ALK+ NSCLC is that advancement is needed to delay disease progression in these patients,” said lead investigator Dr. Enriqueta Felip, Head of the Thoracic Tumors Group, Vall d’Hebron University Hospital. ”These data, coupled with a compelling response in the sub-analysis of patients with baseline brain metastases, provide greater evidence of Zykadia’s potential efficacy in the ALKi-naïve population.”

At the time of analysis, the estimated 18-month overall survival (OS) rate was 73.4% (95% CI: 64.6-80.4). This population also demonstrated an ORR of 63.7% (95% CI: 54.6-72.2) and median duration of response of 23.9 months (95% CI: 16.6-not estimable), according to BIRC assessment. A decrease in tumor burden from baseline was shown in 94.7% patients (investigator assessment only, no BIRC assessment available)[1].

”Novartis is committed to extending lives of patients with difficult-to-treat forms of cancer, and these data presented at ESMO affirm our desire to improve outcomes for those with metastatic NSCLC, specifically,” said Alessandro Riva, MD, Global Head, Oncology Development and Medical Affairs, Novartis Oncology. ”With our first-line Phase III results forthcoming as well as ongoing brain metastases studies, we look forward to sharing further evidence of Zykadia’s full potential.”

Results from the randomized Phase III ASCEND-5 study were also presented for the first time, and were included as part of a late-breaking oral session as well as in the ESMO press program. The ASCEND-5 study assessed median PFS in patients previously treated with crizotinib and one or two prior regimens of cytotoxic chemotherapy (including platinum doublet), who then received either Zykadia or standard chemotherapy. Results demonstrated a statistically significant and clinically meaningful improvement in median PFS by BIRC for patients taking Zykadia versus chemotherapy (HR 0.49, 95% CI 0.36-0.67; p<0.001 one sided). Median PFS by BIRC for Zykadia and chemotherapy were 5.4 months (95% CI: 4.1-6.9) vs. 1.6 months (95% CI: 1.4-2.8), respectively[4].

The ALK gene arrangement, one of the three most common biomarkers – or genetic drivers -of NSCLC, affects approximately 2-7% of cases each year[5],[6]. More than half of these patients are either former smokers or have never smoked[7],[8],[9]. These patients are candidates for treatment with a targeted ALK inhibitor[6].
[1] Felip, E. et al. Phase 2 study of ceritinib in previously treated ALKi-naïve patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC): whole body efficacy in all pts and in pts with baseline brain metastases (BM). Abstract #1208O. European Society for Medical Oncology. Annual Meeting, Copenhagen, 9 October 2016.
[2] Kim, DW. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicenter, open-label, phase 1 trial. Lancet Oncol 2016; 17: 452-463.
[3] Felip, E. et al. ASCEND-3: A single-arm, open-label, multicenter Phase 2 study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC). Abstract #8060. American Society of Clinical Oncology Annual Meeting, Chicago, 1 June 2015.
[4] Scagliotti, G. et al. Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): results from the confirmatory phase 3 ASCEND-5 study. Abstract #LBA42_PR. European Society for Medical Oncology. Annual Meeting, Copenhagen, 9 October 2016.
[5] International Cancer Control: Global Cancer Statistics. Centers for Disease Control and Prevention Website. http://www.cdc.gov/cancer/international/statistics.htm. Last updated February 2015.
[6] National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Non-Small Cell Lung Cancer. NCCN 2014 3:1-148.
[7] Thun MJ, et al. Lung Cancer Occurrence in Never-Smokers: An Analysis of 13 Cohorts and 22 Cancer Registry Studies. PLOS Medicine, 2008. 5(9): e185.
[8] Park E, Japuntich S, Rigotti N, et al. A Snapshot of Smokers After Lung and Colorectal Cancer Diagnosis. Cancer, June 2012. http://onlinelibrary.wiley.com/doi/10.1002/cncr.26545/abstract.
[9] Lovly C, Horn L, Pao W. 2016. Molecular Profiling of Lung Cancer. My Cancer Genome. https://www.mycancergenome.org/content/disease/lung-cancer/. Updated March 2016.